A 12-Week Randomized, Placebo-Controlled Quantitative and Qualitative Evaluation of the Topical Efficacy of Niacinamide Riboside (NR) on Signs of Skin Aging: A Dose Response Comparison in Women Ages 30-60

Inclusion criteria

Open to all races provided they meet the inclusion and exclusion criteria below:

Gender: Female

Age: 30 to 60 years old

Phototype: I to VI

Subject presenting with fines lines/ wrinkles for crows feet, inclusion grade ≥ 3 and ≤ 6 on a 10-points scale.

Subject presenting with one or more visible signs of skin aging on face (example of signs of skin aging: wrinkles and fine lines, lack of firmness, lack of radiance, pigmented spots, a dry and rough skin, visible pores, skin sagging).

Subject is not currently using NAD+ or other product containing Vitamin B3 (niacin, niacinamide, nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, myristyl nicotinate, etc.) administered topically, orally, intravenously, or through any form of injection as a part of their current routine or 4 weeks before starting study. The only permitted exception is the use of a multivitamin that contains niacin or nicotinamide. If this is the case, the product and dose of niacin or nicotinamide should be documented at screening and continuation of use of the product should be documented at each site visit.

Willingness to maintain current lifestyle, wellness and skin care routines (with the exception of the inclusion of the product requirements incorporated into the study protocol).

Exclusion criteria

Subject not providing consent;

Subject not complying with protocol requirements;

Subject of whom a health condition has changed since the inclusion visit in the I.E.C database, making the subject ineligible or places her at undue risk;

Active cancer diagnosis or diagnosis of cancer of any kind less than three years since remission, liver disease, kidney disease, or uncontrolled diabetes;

Pregnancy, actively breastfeeding, or not willing to take necessary precautions to avoid a pregnancy during the study;

Subject having a medical treatment, recent vaccination or expecting to be vaccinated during the study, that makes the subject ineligible or places her at undue risk, in particular, medical treatment (either oral or topical) containing tretinoin or isotretinoin during the 3 months before the starting day of the study;

Subject having a background of intolerance or allergy to cosmetics, NAD+ or any vitamin B3 derivative, ingredients in the auxiliary products or to other substances that makes the subject ineligible or places her at undue risk;

Subject having visible traces of irritation or any other abnormality on the concerned area;

Subject having skin recently exposed to excessive sunlight (natural or artificial) within 4 weeks preceding the inclusion;

Subject having undergone surgery, chemical or physical treatment to the concerned area in the last 12 months (no injection during the last 6 months);

Subject having applied anti-wrinkle/anti-aging/firming products on the areas of concern during the 4 weeks before the starting day of the study;

Subject having had any cosmetic procedures performed in the last six months (including Botox, peels, laser, etc.);

Subject having applied NAD+/B-vitamin products on the areas of concern during the 4 weeks before the starting day of the study;

Subject having modified his/her cosmetic habits (on the areas concerned by the study) during the last 2 weeks, making her ineligible;

Subject having applied cosmetic or pharmaceutical products (other than their usual cleanser) to the areas of concern during the 96 hours before the starting day of the study and on the day of inclusion;

Subject having applied any cosmetic or pharmaceutical products (only water allowed) to the areas of concern the day of inclusion.